143 related articles for article (PubMed ID: 25449686)
1. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
2. Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia.
Kawai H; Matsushita H; Suzuki R; Sheng Y; Lu J; Matsuzawa H; Yahata T; Tsuma-Kaneko M; Tsukamoto H; Kawada H; Ogawa Y; Ando K
Leuk Res; 2014 Dec; 38(12):1451-9. PubMed ID: 25217890
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein.
Kawai H; Matsushita H; Suzuki R; Kitamura Y; Ogawa Y; Kawada H; Ando K
Neoplasia; 2019 Aug; 21(8):788-801. PubMed ID: 31276931
[TBL] [Abstract][Full Text] [Related]
5. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
6. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Kantarjian H; Branford S; Breccia M; Cortes J; Haddad FG; Hochhaus A; Hughes T; Issa GC; Jabbour E; Nicolini FE; Sasaki K; Xavier-Mahon F
Leukemia; 2024 May; 38(5):947-950. PubMed ID: 38531949
[No Abstract] [Full Text] [Related]
7. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
Langabeer SE; Haslam K; Crampe M; MacDonagh B; McHugh J
Exp Oncol; 2019 Mar; 41(1):82-83. PubMed ID: 30932408
[No Abstract] [Full Text] [Related]
8. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
10. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
11. SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
Biloglav A; Olsson-Arvidsson L; Theander J; Behrendtz M; Castor A; Johansson B
Genes Chromosomes Cancer; 2020 Sep; 59(9):540-543. PubMed ID: 32306475
[TBL] [Abstract][Full Text] [Related]
12. Linking miRNA regulation to BCR-ABL expression: the next dimension.
Faber J; Gregory RI; Armstrong SA
Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
[TBL] [Abstract][Full Text] [Related]
13. Research in the heart of hematology: chronic myeloid leukemia 2017.
Hehlmann R
Haematologica; 2017 Mar; 102(3):418-421. PubMed ID: 28250004
[No Abstract] [Full Text] [Related]
14. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
[TBL] [Abstract][Full Text] [Related]
16. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
[No Abstract] [Full Text] [Related]
17. t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia.
Sheng G; Zeng Z; Pan J; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Acta Haematol; 2017; 137(1):40-43. PubMed ID: 27894117
[No Abstract] [Full Text] [Related]
18. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Tanasi I; Ba I; Sirvent N; Braun T; Cuccuini W; Ballerini P; Duployez N; Tanguy-Schmidt A; Tamburini J; Maury S; Doré E; Himberlin C; Duclos C; Chevallier P; Rousselot P; Bonifacio M; Cavé H; Baruchel A; Dombret H; Soulier J; Landman-Parker J; Boissel N; Clappier E
Blood; 2019 Oct; 134(16):1351-1355. PubMed ID: 31434701
[No Abstract] [Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
